The world of thoracic surgery is undergoing a profound transformation, and a recent meta-analysis by Bertoglio and colleagues is shedding light on the impact of neoadjuvant chemoimmunotherapy on surgical outcomes for resectable non-small cell lung cancer (NSCLC). This analysis, published in 2026, is a beacon of clarity in an era where the rise of immunotherapy has blurred the lines between oncologic and surgical practice.
The Surgical Implications of Immunotherapy
The question of whether preoperative immunotherapy makes surgery more difficult or dangerous is no longer theoretical. As checkpoint inhibitors have moved into earlier-stage NSCLC, thoracic surgeons are increasingly operating in tissues altered by immune activation, inflammation, and fibrosis. This shift in the landscape of lung cancer treatment demands a reevaluation of surgical techniques and strategies.
The meta-analysis by Bertoglio et al. provides a comprehensive overview of surgical outcomes after neoadjuvant chemoimmunotherapy. It includes 27 trials involving 2,691 patients, offering a robust dataset to explore the feasibility and safety of surgery in this context.
Reassuring Findings, But Not Without Challenges
The good news is that surgery after immunotherapy-based treatment remains achievable and generally safe. The pooled event proportions for intraoperative complications, postoperative complications, and postoperative mortality are 0.03, 0.27, and 0.01, respectively. These numbers suggest that surgery remains a realistic and acceptable part of multimodality treatment, even after neoadjuvant or perioperative immunotherapy-based therapy.
However, the analysis also highlights the technical burden that accompanies these operations. Minimally invasive surgery was used in 47% of resections, with a 20% conversion rate to thoracotomy. Surgical delay occurred in 9% of cases, and pneumonectomy was required in 10%. These figures indicate that even if mortality remains low, surgery after neoadjuvant immunotherapy is not identical to upfront surgery and may demand more flexibility, experience, and a higher level of readiness to escalate the operative approach when needed.
Chemoimmunotherapy vs. Immunotherapy Alone
A meta-regression comparing chemoimmunotherapy protocols with immunotherapy-only regimens revealed nuanced findings. Chemoimmunotherapy was associated with higher rates of intraoperative complications and surgery omission, while immunotherapy-alone regimens were linked to higher postoperative mortality. These results suggest that not all immunotherapy-based preoperative regimens shape surgical risk in the same way, and surgeons should not assume that all neoadjuvant immunotherapy strategies are surgically interchangeable.
Implications for Thoracic Surgeons
For thoracic surgeons, the practical implication is that surgery after immunotherapy should be approached as a different technical setting from untreated resection. Immune-related tissue effects may complicate hilar dissection, blur anatomic planes, and increase the chance that a minimally invasive plan will need to be converted. This does not make surgery inappropriate, but it means surgeons should anticipate difficulty earlier, plan more carefully, and work in settings where anesthesia, oncology, radiology, pathology, and postoperative support are tightly integrated.
The authors emphasize the importance of multidisciplinary coordination and centralization. While not every resectable NSCLC case needs to be concentrated in a referral center, experience matters more once surgery follows checkpoint inhibitor-based therapy, especially in borderline resectable or more locally advanced disease.
The Oncologic Era and Surgical Culture
One of the most interesting tensions exposed by this paper is the rapid advancement of oncology into the perioperative immunotherapy era, while surgical evidence has lagged behind. Major trials have established pathologic and survival benefits, but the surgical literature has often consisted of smaller institutional experiences, heterogeneous definitions of complications, and mixed impressions about technical difficulty.
The meta-analysis helps stabilize this conversation by showing that surgeons are not facing a catastrophic postoperative environment after chemoimmunotherapy. However, it also confirms that the technical concerns are real enough to justify caution. This balance is valuable, protecting against excessive fear that might make surgeons hesitant to operate and excessive enthusiasm that might underestimate the demands of these procedures.
Limitations and Future Directions
The authors acknowledge several limitations, including substantial heterogeneity in some key outcomes and the fact that these were prospective trial populations, not broad real-world cohorts. These limitations define how the study should be used as a high-quality overview of surgical feasibility in the immunotherapy era, rather than a rigid prediction tool for every operating room.
In conclusion, this meta-analysis supports the conclusion that surgery after neoadjuvant or perioperative immunotherapy-based therapy for resectable NSCLC is feasible and safe, but it is not surgically neutral. Postoperative mortality remains low, intraoperative complications are uncommon, and resection remains achievable in most appropriately selected patients. However, conversion, delay, omission, and technical complexity remain real concerns, especially as treatment protocols differ. The strongest practical message is that surgery should increasingly be done in coordinated multidisciplinary programs with surgeons who are experienced in operating after modern systemic therapy.
